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North and carried out in the South. Ethical research should contribute to social value in the country where research is being carried
out, but there is significant debate around how this might be achieved and who is responsible. The literature suggests that re-
searchers might employ two inter-related strategies to maximise social value: collaborative partnerships with policy makers and
communities from the outset of research, and dissemination of research results to participants, policy makers and implementers
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interviews to explore the role of collaborative partnerships in health research priority setting, and the way in which research findings
are disseminated to aid policy making and implementation in Kenya. Interviewees included policy makers, researchers, policy im-
plementers and representatives of organisations funding health reforms in Kenya. Two policy issues were drawn upon as tracers
wherever possible: (1) the introduction of Artemesinin- based Combination Therapies (ACTs), an anti-malarial treatment policy;
and (2) Haemophilus influenzae (Hib) vaccine for the prevention of pneumococcal diseases among children.
The findings point to significant gaps in the ‘research to policy to practice’ pathway, particularly for national research institu-
tions with a focus on clinical/biomedical research. These gaps reflect poorly effective partnerships among stakeholders and limit the
potential social value of much research. While more investment is needed to establish strong structures for promoting and directing
collaboration and partnership, how to target this investment is not entirely clear, especially in the context of the considerable power
of the global health agenda and the research financing tied to it.
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Discussion of the ethics of research involving human
subjects often focuses on research design and approval,
and on how individual research participants’ rights and
welfare are to be protected during health research. How-
ever, as research sponsored by government agencies,
foundations, and private companies in developing coun-
tries has increased, growing attention is being paid to
the ethical questions that arise when a study is con-
cluded. These questions include: what, if anything,
should be provided to research participants, and by
whom, after their participation, and what, if anything,
should be made available to others in the host commu-
nity or country following completion of the research
(Benatar & Singer, 2000; Bhutta, 2004; Emanuel,
Wendler, & Grady, 2000; Nuffield Council on Bioethics
(NCOB), 2005; Ogundrin, 2004). These questions raise
complex ethical, social and policy issues.
It is now widely recognized that an important
ethical aspect of research practice ought to be the
consideration of its capacity for generating social
value locally through the generation of knowledge
that can lead to generalized health improvements
(Emanuel, Wendler, Killen, & Grandy, 2004). The
importance of considering social value has gained
prominence for several reasons. First, the perceived
potential benefits of research to the entire population
are increasingly used as a powerful justification for
conducting different types of health-related research.
Second, there is an increasing realization that most
research does not get into practice and that translating
research into health improvements is complex, incre-
mental and haphazard (Graham et al., 2006; Kerner,
2006; Lavis, 2006; Pablos-Mendez & Shademani,
2006). Although this is not unique to developing coun-
tries, the situation is exacerbated by weak health care in-
frastructure and resource constraints (Black, 2001).
Third, there is a concern that in the absence of an infra-
structure that translates research results into health
system improvements in developing countries, it is
individuals or communities that assume any risks of
research while the benefits accrue either to researchers
themselves, through career enhancement, or to research
sponsors who are recognized for their scientific profile
(Benatar, Singer, & Daar, 2005; Emanuel et al., 2004).
Most international guidelines on the conduct of research
are relatively silent on the issue of how the social value
of research might be promoted. This poses particular
challenges for researchers, ethical review committees,
sponsors and regulatory bodies especially where the jus-
tification for research is in part or whole to obtainbenefit for the wider population (Grady, 2004; Grinyer,
2001).
Emanuel et al.’s recent paper distils existing ethics
documents to draw up a framework to assist re-
searchers and research ethics committees assess how
well ethical principles are being fulfilled in practice
in developing countries. They suggest considering a se-
ries of benchmarks in relation to eight key ethical prin-
ciples. Social value and collaborative partnership are
the two principles that focus on the public good/bene-
fits coming from research, as opposed to more individ-
ual considerations. Special attention is given to the
principle of collaborative partnership in low income
settings. It is premised on the need to minimise the
possibility of exploitation of research participants by
ensuring that researchers and sponsors from developed
countries work together with local researchers, policy
makers and communities in the developing world to
determine the health priorities that should be the sub-
ject of research. In addition, this partnership is meant
to provide a conduit through which research findings
can influence policy decisions and practice. Ultimately,
therefore, research findings should continue to
strengthen the partnership by helping to define prob-
lems and priorities e part of their social value. Four
benchmarks are proposed for judging the potential
social value of research and five for the collaborative
nature of partnerships (Table 1).
Initially, our research focused on how these two
principles are considered by key stakeholders in
Kenya. The work later evolved to focus on one bench-
mark for each principle. The benchmark on shared re-
sponsibility in agenda setting, and the mechanisms
used for dissemination, was chosen for collaborative
partnership and social value, respectively, to explore
attempts to add value to the research findings. These
two were chosen due to their broad nature and likeli-
hood of encompassing critical issues addressed by
the other benchmarks under the two principles.
In Kenya, like most other countries, there are wide
gaps between health research, policy and practice
(Bero et al., 1998). There has been a flurry of activities
in support of collaboration and partnership between
researchers, policy makers and other stakeholders as
a strategy of closing these gaps but these have not
been extensively researched. However, even in cases
where the studies have underscored the need for such
partnerships, this has not been considered as an ethical
imperative. The study was therefore conducted to be-
gin to explore, using an ethical perspective, the nature
of collaborative partnerships in Kenya, focusing on
research agenda setting and how the efforts to
Table 1
Ethical principles and benchmarks for multinational research (Emanuel et al., 2004)
Principle Benchmarks
Collaborative partnership  Identify local partners
 Shared responsibility for identify importance of health problem
 Respect for community value
 Minimal disparities between researchers and sponsors
 Fair benefits
 Determine beneficiaries
Social value  Outline potential value of research to each beneficiary
 Mechanisms to enhance social value
 No supplanting extant health system
Scientific validity  The scientific design realizes scientific objectives
 Study is feasible within local healthcare & physical infrastructure
Fair Selection of study population  Selected population should ensure scientific validity
 Select population to minimize the risks of research & enhance other principles
 Identify & protect vulnerable pops
Favourable risk-benefit ratio  Assess potential risks & benefits of research
 Compare net risks with potential benefits
Independent review  Ensure reviews by bodies mandated by laws and regulations
 Transparent reviews by international bodies as appropriate
 Ensure independence & competence of reviews
Informed consent  Involve community in recruitment procedures & incentives
 Disclose information in linguistic & culturally acceptable formats
 Implement supplementary consent procedures where appropriate
 Obtain consent in culturally acceptable format
 Ensure freedom to participate
Respect for participants  Develop & implement procedures to protect confidentiality
 Ensure participants know their rights
 Give participants information arising from the study
 Monitor & develop interventions for medical conditions arising from participation
 Feedback findings
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for this exploration developed from discussions be-
tween investigators and policy makers at the Ministry
of Health about the need to develop cohesive working
relations between them in tackling the disease burden
of interest in the country.
Context
Health research is conducted in Kenya by a number
of institutions comprising both government and non-
governmental bodies. The government bodies include
universities (under the Ministry of Education) and the
institutions under the Ministry of Health (MoH), such
as the Kenya Medical Research Institute (KEMRI). In
theory, research by these bodies is supposed to be
harmonised and integrated into the policy making
process of the MoH through various inter-agency
coordinating committees (ICCs) (Fig. 1), which them-
selves were recently established in line with key
priority areas as defined in the MoH 2005e2010
strategic plan.Policy implementation on the other hand is the re-
sponsibility of the provincial and district health tier
(Fig. 2, Oyaya & Rifkin, 2003), under the guidance of
the provincial and district medical officers, respectively.
The PMOs are responsible for the interpretation, guid-
ance and monitoring of the implementation process,
while DMOHs in conjunction with the district health
management teams (DHMTs) are responsible for imple-
mentation (Owino, 1997).
Methods
Design
The study was aimed at assembling a broad over-
view of the research to policy and practice interface
for research findings in Kenya using an ethical perspec-
tive. While there was no intention to examine a specific
policy or set of policies, where appropriate during inter-
views, we used two major Kenyan health policy issues
as examples to help illustrate questions and ground
them in practice. These findings, then, are likely to
(Policy level)JICC
Malaria ICC RH ICC HIV/Aids ICC Child health ICC
PMO (PHMT)
DMOH
(Operational level)
Division
Village
Global Initiatives
(Programmes)
(DHMT)
Fig. 1. Location of inter-agency coordinating committees within the ministry of health. JICC e Joint Inter-Agency Coordinating
Mechanism (a mechanism for overseeing the functions of all individual ICCs); ICC e Inter-Agency Coordinating Mechanism; PHMT
e Provincial Health Management Team; DHMT e District Health Management Team; DMOH e District Medical Officer of Health;
RH e Reproductive Health.
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tracers and organisations interviewed.
The two policy issues (tracers) were the change of
anti-malarial drug policy from sulphadoxine/
pyrimethamine drugs (SPs) to Artemisinin-based
Combination Therapies (ACTs), and the introduction
of Haemophilus influenzae type B (Hib) vaccine.
The introduction of ACT was chosen because the
decision for the policy change was made rapidly,
largely on the basis of strong evidence of failure of
the existing first-line drugs, but with limited locally
generated efficacy data for the proposed ACT. The
Hib tracer was chosen because of apparent concerns
that it was pushed into the country with little collab-
oration and initially lacked local data to support its
relevance.
The process of changing the anti-malarial treatment
policy to ACTs started in 2003, following increasing re-
sistance of the major malaria parasite (Plasimodium
falciparum) to sulphadoxine-pyrimethamine (SP) drugs
that were then the recommended first-line treatment.The recommendation by the World Health Organisation
(WHO) to countries experiencing drug resistance to SP
was (and is) to change to combination therapies, a view
strongly endorsed by local technical and research
experts. The policy change was announced by the Min-
ister of Health in April 2004.
The Hib vaccine, on the other hand, was introduced
in 2001 based primarily on evidence of vaccine effi-
cacy from The Gambia. The initial funding commit-
ment for the vaccine came from the Global Alliance
for Vaccines and Immunisation (GAVI), with an initial
agreement that the Government of Kenya would as-
sume responsibility for vaccine financing arrangements
(with partners if required) after the expiry of the initial
support. This agreement assumed a widely anticipated
and significant fall in the price of the Hib vaccine, an
assumption that has proven to be incorrect. At the
moment, the Ministry of Health has signed up for three
years ‘‘bridge financing’’ support from GAVI, but
currently there is no commitment to fund the vaccine
any longer than this.
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Fig. 2. MoH levels of responsibility (adapted from Oyaya & Rifkin, 2003).
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For this study, a broad definition of health research
was used to allow inclusion of a broad spectrum of
stakeholders. Health research is defined as the genera-
tion of new knowledge, using the scientific method, to
identify and deal with health problems (Council on
Health Research for Development (COHRED), 1990).
The respondents included senior policy makers andimplementers at the central, provincial and district level
of the ministry of health, senior representatives from
national research institutions, major non-governmental
organisations (NGOs) and other bodies undertaking re-
search, as well as bilateral bodies that help fund health
reforms in Kenya. To identify participants, a list of
institutions undertaking health research in Kenya was
obtained from the National Council for Science and
Technology (NCST), which is the oversight body
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search. Non-governmental organisations were identified
from the NGO coordination board, which is the body in
charge of their registration. A short questionnaire was
sent to these organisations, requesting information on
the broad research areas that they focused on, and this
was later followed with a telephone call to ensure a re-
sponse. From this list, institutions were purposefully
selected depending on their relevance to the topic under
investigation, to include senior research scientists
from KEMRI and the University of Nairobi among the
national research institutions, and directors of research
programmes from the Population Council, African Pop-
ulation and Health Research Centre, Populations Ser-
vices International, Futures Group and the Family
Planning Association of Kenya from among organisa-
tions involved in programme-based research. Funding
agencies included UNICEF (United Nations Children’s
Fund), DFID (Department for International Develop-
ment), and DANIDA (Danish International Develop-
ment Assistance).
Procedures and data collection
Key informant interview guides were used for data
collection. These were developed after reviewing two
bodies of relevant literature; one on ethics of health re-
search in developing countries and the second on the
utilisation of research in health policy making and
practice. These guides were pre-tested to assess their
appropriateness for collecting the intended data, and
changes were made accordingly. They were, however,
continually modified during the data collection to cap-
ture emerging issues. Interviews were tape-recorded
and supplemented with back-up notes. Data on collab-
orative partnerships were elicited by asking questions
on the basis for and actors involved in setting the
agenda for health research, and by exploring efforts
made to integrate the research findings into the health
system more generally and on the two tracers in partic-
ular. Data on mechanisms used for disseminating re-
search findings were elicited by asking participants
what strategies were used for communicating or shar-
ing their research findings with the intended users.
Prior to the interviews, consent was sought from partic-
ipants. The process included sending, in advance,
a short description of the project explaining the study
objectives, voluntary participation, right of withdrawal
and the fact that comments would not be attributed to
the respondents. These were further explained to them
on the interview day. The principal investigator tran-
scribed the interviews and sent back the transcripts toparticipants for verification. Transcripts were then
stored in a password-protected database and the tapes
in a secure place for back-up. In total, 40 interviews
were conducted, comprising 11 policymakers, 14 policy
implementers, 12 researchers and 3 health advisors.
Data analysis
Data analysis and management were performed
using NUD*IST N6 (QSR International Pty Ltd.,
Australia). Data were explored and interrogated using
a priori codes developed from our literature review.
Similar data were grouped conceptually, labelled and
concepts categorised and linked. An attempt was
made to compare and contrast data across different
categories of respondents where feasible and to further
corroborate and triangulate with previous literature on
ethics of research and utilisation of research in policy-
making and practice. Selected transcripts were shared
among three researchers who independently identified
themes and later held a consensus meeting to identify
the analytical themes.
Findings
The findings are presented along two broad themes
discussed in the interviews; the process and basis for
agenda setting for health research, and the integration
of research into policy and practice through dissemina-
tion. Specific insights from the two policy tracers are
also presented, followed by a discussion on how these
findings illustrate gaps in collaboration and partner-
ship, and in promoting social value.
Research agenda setting: who sets the agenda, on
what basis and at what level?
Shared responsibility for assessing the importance
of the health problem and the potential value of
research to the community, planning, conducting re-
search, disseminating findings and the integration of
evidence into the health care system is one benchmark
of collaborative partnership (Table 1; Emanuel et al.,
2004).
Generally, there was a consensus among the differ-
ent categories of respondents that the health priorities
as set out in the National Health Sector Strategic
Plans 1 and 2 addressed diseases with the highest
burden for the country (MoH, 1999; MoH, 2005).
These include malaria, HIV/AIDS/STI and TB, child
health, safe motherhood and the control of environ-
ment-related communicable diseases. Our purpose,
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and health policy in more detail and the extent to
which there was shared responsibility in the identifi-
cation of the key issues and their prioritisation. We
considered comments around research agenda setting
among the four categories of respondents, namely:
policy makers at the central level at the MoH, donors
funding health reforms in Kenya, researchers in-
volved in health research and actors perhaps most
representative of communities, the provincial and dis-
trict level policy implementers. While we did not
specifically explore the role of grassroots advocacy
groups, interestingly, these were not mentioned as
contributing to the process of research agenda setting
during our interviews.Health policy and research links
Policy makers’ views
The policy makers reported that the policy agenda
for health was determined based on the morbidity
and mortality data from the health facilities in the
country, and other sources of data such as the Kenya
Demographic and Health Survey (KDHS).
.Well as far as I know, they (MoH planners) look
at the statistical issues in terms of the disease bur-
den patterns. These are derived using data from
the health information systems, these random sur-
veys and the KDHS. The provision of such data is
also the responsibility of other providers in the
health facilities. But whether this data is accurate
or efficiently done, that’s a different issue. (Policy
maker 2, M, 10.03 2005).Funders’ views
Those funding the health reforms on the other hand
said that their health policy decisions were based on
evidence from specifically commissioned situation
analyses and other information gathered through in-
ter-sectoral coordinating committees.
..Our Programmes as elsewhere in the world are
derived from an assessment of the country situation
and also the global challenges that have to be met.
For instance now there are the millennium develop-
ment goals and there have also been other global
challenges in the past. So based on the country sit-
uation as well as the global challenges, we agree
with the government on which area of priority will
be supported.(Health advisor 3, F 14. 04. 2005).Policy implementers’ views
Despite the reports by both policy makers and some
researchers (see below) that data from the districts
were used as the basis for determining the health policy
agenda, policy implementers felt they were not mean-
ingfully involved in the process:
.You see it is always made clear to us that we are
not policy-makers but policy implementers and it’s
not our business to determine the focus of the min-
istry.and we have taken our position. this is the
situation that we have always found ourselves in.
(Policy implementer 7, M, 25.05 2005).Researcher’s views
Although clearly crude, it is illustrative to think of
two forms of institutions conducting health research
in Kenya: (1) those that are involved in both implement-
ing health programmes and conducting research; and
(2) institutions or groups whose main mandate is to
conduct research in order to contribute to knowledge
as a national and global public good. Programme-based
health researchers reported that their health research
agenda was primarily determined by their overall man-
date and mission. They also mentioned, however, that
efforts were made to corroborate their mandate with
the local health agenda.
.It’s generally the mandate of the organization.
Our philosophy is that the role of our research
must be practically useful to the country where we
work, either at the policy or program level or just
at the service delivery level.(Researcher 4, M,
31, 03 2005).
Researchers from the national research institutes
reported conducting research on the priority areas
already identified by the MoH:
. During the different workshops that take place in
different parts of the country, we identify what are
the needs and what issues are, and of course, we
also use the records, although shamefully not up-
to-date, the records being given by the MoH through
their own annual reports, then we will be able to
identify what the MoH thinks should be done..
(Researcher 1, M, 12.04.2005).
. So these days, when we want to do research, we
have to look at what is the direction of the MoH in
terms of what kind of diseases they want to be
addressed by research. (Researcher 2, M,
08.03.2005).
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also emphasised the importance of having a broader
health research remit as opposed to only following
the agenda set by the MoH:
.Research ought to do more than address priorities
.we have researchers here who are experts in their
own right, they understand what issues are going on
in various fields, they have done research and they
have published extensively in their own work and
therefore they are able to understand the gaps in
knowledge and then raise questions around tho-
se.So we formulate them (research priorities)
through an iterative process where you address
one question, come up with other questions and
you look at them and extend the boundaries of
knowledge (Researcher 5, M, 24.03.2005).The role of global over local priorities in health
policies and health research
Despite the links described above, there was a clear
feeling among some policy makers and institute-based
researchers that the national priorities for health, which
ultimately shaped the agenda for research, were de-
cided with heavy input from those funding health re-
forms in the country. Thus the national health
priorities were considered to be more representative
of a global rather than local health agenda:
.The need for reforms as brought out in the strate-
gic plan was mainly pushed by the WB and WHO
and the main focus was the need to redefine the
health priorities for the country, seek ways and
means for improving the quality of health services
offered as well as ensuring the services are afforda-
ble.(policy maker 11, M, 28.06.2005).
The relative lack of power of national actors is also
suggested by the frequency with which inadequacies of
local health data were highlighted as a problem in set-
ting local priorities. Data drawn from discussion about
from the ACT tracer, for instance, suggest that al-
though there were local data showing that resistance
to sulphur-based anti-malarial drugs exceeded the
WHO threshold, the MoH did not make the decision
to adopt the ACTs until the entry of the WHO into
the drug policy change arena.
. Since the year 2000, we have known that we have
a mounting resistance to sulphur based drugs and it
has taken us too long for the policy-makers to make
a decision that we need to change. It’s only when
the WHO started pushing these things of ACTs thatthe debate started. Again you see these things are
pushed more by a drug company rather than the
policy-makers. (Researcher 8, M. 23.06.2005).
Some of the institute-based researchers also consid-
ered that they ought to be autonomous in the choice of
research topic and to be independent in terms of the
ability to challenge accepted dogma and take a longer
term, more forward-thinking institutional view. It was,
however, reported that this latter function was con-
strained, primarily by lack of resources, which led
most of the research activities to revolve around the
relatively resource-rich globally defined agenda.
.In my opinion, to tell you the truth, the research
that goes on here is actually donor funding oriented,
and of course we know that a lot of donors really
look at what the country wants to do. Like currently
in the areas of HIV/AIDS, malaria and TB, there is
a lot of funding, and you have to write a protocol
where you can get funds, and not just because it is
important (Researcher 3, F, 18 .04. 2005).Dissemination of research findings: mechanisms and
challenges
Enhancing the value of the research through dissem-
ination of findings, product development, long-term
collaboration, and/or health system improvements is
one benchmark of social value (Table 1; Emanuel
et al., 2004). We describe various mechanisms reported
to be in place for ensuring that research findings were
disseminated to policy-makers, the implementers and
other category of users.Dissemination to policy makers
There was consensus among institute- and pro-
gramme-based researchers that research findings
should play a key role while addressing local health
needs by directly informing policy making and sup-
porting the implementation of such policies. Research
findings were reported to be mainly disseminated
through publication in journals, presentation in work-
shops/seminars/conferences or teaching at universities.
General mechanisms for dissemination without
careful consideration and targeting of potential users
at different levels was reported to be common among
institute-based researchers.
. the culture is to do research and publish and
forget about it, and possibly be promoted. That’s
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educated about the need to disseminate their results
in a manner that it can have impact on policy; not
just for scientific journals.(Researcher 2M, 08 03
2005).
. we do not lobby the ministry of health for the
adoption of our findings. We do the research and
say hey look we have data here that shows this or
that, what do you say about this? And then the
MoH will pick from there. And even then, this in-
formation is not only provided to the MoH but
also published in peer reviewed journals and it’s
therefore available to everybody who wants it, and
they can use it to reach their own conclusions
(Researcher 11, M, 19.04.2005).
Programme-based researchers were more likely to
use interactive methods of dissemination, targeting
specific classes of users. This is linked to their major
concern of ensuring that their research output can be
integrated into the existing health system. Some form
of networking with policy-makers was often reported,
often long before the study is complete:
.What we tend to do with ministries or academic
bodies or key NGOs is to engage them more at in-
dividual levels, to try and pick key people that we
should be talking to, may be at the PS level, the
DMS at the MoH level or departmental heads, and
just try to work with them to make sure that they un-
derstand results of research and they can use that to
inform their decisions. So we do try to engage them
directly, and if possible, these are the first people
that we talk . (Researcher 4, M, 31, 03 2005).
It was reported, though, that these interactive
methods of dissemination have many challenges. For
instance, local stakeholders including the policy-
makers and implementers were rarely involved while
designing the study and therefore there was no guaran-
tee that the resultant research findings addressed issues
of relevance to them. In addition, these mechanisms
were based on acquaintances, thereby locking out
actors who are as yet not well known in the field.
Third, the absence of formal structures to govern
such relationships made them cumbersome and unreli-
able. In particular, difficulties were reported in trying
to nurture and maintain informal networks beyond
the life of a project or in the wake of staff turn over,
a common feature of the public service:
‘‘.You need to realize that there have been several
changes within the ministry of health that we have.Three years ago, we had a different government in
place and now we have different people in majority
of the departments of the MoH. So maintaining
those links has not been easy. Again you look at
the relative cost of investing in these relationships.
Even if five people in the ministry know what you
are doing, what is it compared to maybe hundreds
of different offices that make decisions indepen-
dently, .(Researcher 5, M, 25.03. 2005).
Among the more formal mechanisms for dissemina-
tion used by researchers were presentation of brief re-
ports to policy-makers or use of dissemination seminars
with a specific invitation list including fellow researchers,
policy-makers and sponsors, and the establishment of
project steering committees involving policy-makers.
Steering committees were used as sounding boards,
and met occasionally to deliberate on emerging issues
from the research. The effectiveness of these mecha-
nisms was constrained by lack of resources to
specifically address the post-research phase, the limited
number of senior policy-makers that every project could
target, and the inability of researchers to use jargon-free
language to disseminate to potential users. On the de-
mand side, it was reported that there was little appetite
for academic research whose focus is to extend the fron-
tiers of knowledge but often lacks immediate practical
application to problem solving.
Dissemination to participants and policy implementers
Concerns were expressed by policy implementers
that researchers did not share findings with participants
or even, where relevant, the facilities where research
was conducted. The only exception was when policy
implementers were co-opted into research projects.
As a result, some of the PMOs and DMOHs reported
contemplating barring the conduct of research at their
facilities unless there was a commitment to dissemi-
nate findings upon completion.
.In this country, we have not only research insti-
tutes but also individuals who do research from var-
ious institutions of higher learning. Unfortunately I
will say that there has not been a uniform way of
harnessing research findings because these individ-
uals when they come here, they have letter of au-
thority from the office of the president so that we
can allow them to conduct research. Most of the
times, they leave after the data collection but they
never ever feed back on their findings and so we
don’t have a data bank of research that has been
conducted at the institution. I think we need to
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(Policy implementer 4, M, 13 07 2005).
Policy-makers too, felt that research evidence should
play an important role in supporting policy implementa-
tion. However, such sentiments were not matched by
practice: no specific initiative was reported to be in
place for delivering research evidence to policy imple-
menters to support a policy action. This is despite the
existence of a defined structure from the JICC to the
DHMT (Fig. 1) within the MoH, intended to serve this
purpose. In the case of anti-malarial drug policy change,
the PMOs and DMOHs reported that the evidence be-
hind the decision to adopt ACTs was not disseminated
to them. Instead, only sensitisation seminars were re-
ported to have been held, and used for communicating
the policy direction as opposed to sharing evidence.
.I think there is very little collaboration in that
field because research is done up there, they can dis-
seminate or share the findings with the stakeholders
and in this case it’s generally the Ministry of Health,Box 1. Anti-malaria drug policy change to ACTs
.Well, we kept showing it [resistance to chloroqu
care until early 90s because they had not seen the
tinued to be a wide gap between policy makers an
about the real problems that the country was goin
other hand saying there is no problem, we haven
.Since the year 2000, we have known that we h
drugs and it has taken us too long for the policy
change. It’s only when the WHO started pushing
Again you see these things are pushed more by a d
(Researcher 8, M. 23.06.2005).
.We have technical working groups and one o
group, and following advice from WHO asking c
the drugs with a view of adopting more effective
hitherto not been very active was revitalized (Poli
.But the adoption of the guideline (policy on ACTs
the signing of the Round Four global forum on HIV
cause this is an expensive policy, and a top policy-
Four is signed they were not going to announce
lines (Policy-maker 6, M, 05 04 2005).
. The problem is that you read these things in ne
myself, nobody bothers to communicate this to us
laria Control), and tell you, now this is the new m
ported by this and that research (Policy Implemenand they do that at the ministry level or the people
from the programmes, and therefore they will form
policy from there and we will be called to be up-
dated. That’s in terms of communicating policy
but that’s just about it and in terms of giving us re-
search findings there is nothing. (Policy Imple-
menter 4, M, 26.05.2005).
Insights from the ACT and Hib vaccine tracers
Data from the two tracers provide some specific
insights into the consequences of failure to negotiate
adequately, the prioritisation of health problems and
the impact of weaknesses in mechanisms for sharing
evidence among stakeholders. In the ACT case, re-
search evidence addressing a local problem delivered
through the malaria Technical Working Group
(TWG) played a key role in influencing the technical
content of the policy shift from SP drugs to ACTs. In
spite of this, the delays in actual policy implementation
(see Box 1) illustrate the limited power of scientificine] in our annual presentation but they didn’t
clinical numbers. This is because there con-
d scientists. So the scientists kept on talking
g to face and the policy makers were on the
’t seen it (Researcher 2,M, 08.03 2005).
ave a mounting resistance to sulphur-based
-makers to make a decision that we need to
these things of ACTs that the debate started.
rug company rather than the policy makers.
f them is the drug policy technical working
ountries that had failing drugs to re-look at
medication, this technical group which was
cy-maker 6, M, 05 04 2005).
) were delayed because they were pegged on
/Aids, Tuberculosis and Malaria (GFATM), be-
maker said that unless the Global Fund Round
anywhere that they have accepted the guide-
wspapers even as a provincial physician like
, for instance from the DOMC(Division of Ma-
alaria drug policy and that this has been sup-
ter 3, M, 26.05.2005).
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a relative failure in recruitment of wide support for
the policy shift as a result of weak mechanisms for
sharing information, notably with policy implementers.
The introduction of the Hib vaccine on the other
hand (Box 2) provides a sharp contrast in that initial
collaboration between local stakeholders and the part-
ners who are willing to finance the vaccine was defi-
cient. In this case, the Global Alliance for Vaccines
and Immunisation (GAVI), UNICEF and the World
Health Organisation (WHO) reportedly spearheaded
the introduction of the vaccine in Kenya in 2001, based
primarily on evidence of vaccine efficacy from The
Gambia. However, it appears that the absence of local
data on or appreciation for the burden of Hib disease
prior to vaccine introduction and the perceived urgency
with which the vaccine was introduced all contributed
to the feeling that donors pushed the vaccine into the
country. Thus, although there is now emerging evi-
dence (Cowgill et al., 2006) that the vaccine is a valu-
able tool to help reduce childhood mortality and
morbidity, this research data may not reach an audi-
ence both receptive and large enough in time to influ-
ence a decision on its future as a component of the
government immunisation programme. In a nutshell,
the cases above show how lack of collaboration in
the identification of key issues and lack of proper
mechanisms for disseminating research findings to
potential users can be a deterrent to achieving the
social value of research by failing to influence policy
and practice.Box 2. Introduction of Haemophilus influenzae typ
.The introduction was spearheaded by GAVI, W
mised on the prevalence of pneumonias and me
sence of effective vaccines to counter them. This
Africa, although there were no local data from th
a bit hesitant to buy the ideas, but again there
were saying, and you know how donors are push
.In a way, the policy-makers here, besides succu
in the introduction of the vaccine in terms of infra
efits (Policy-maker 8, F, 04. 04 2005).
.Personally I think there was no basis for the intr
operations research. to establish what the impac
(Policy-maker 8, F, 04. 04 2005).
.You see we should actually be getting updates o
monias have gone down as a result of giving the v
9, M, 09.06.2005).Discussion
Collaboration and partnership among researchers,
policy-makers and policy implementers can play a sig-
nificant role in ensuring that research is responsive to
a community’s health problems by influencing and sup-
porting appropriate health policies and their implemen-
tation (COHRED, 2001; Edejer, 1999; SCRPDC, 2002;
Volmink & Dare, 2005; Wilson, 1999). This can, how-
ever, only occur in the presence of strong structures for
coordination and leadership of such partnerships, sup-
ported by an attendant capacity to define an appropriate
health agenda among local stakeholders. A country’s
agenda for health provides a roadmap which informs
both research and policy priority setting (Feranil,
2004). The process of setting the agenda can therefore
be instrumental in closing the gap between research
knowledge and practices. An exploration of the actors
involved in setting the agenda for research, knowledge
production and the mechanisms for sharing this knowl-
edge in Kenya provides some critical lessons on what
the gaps between research, policy and practice are,
and what perpetuates them. Addressing these gaps is
increasingly felt to be an ethical obligation for
researchers and funding bodies.
How the agenda for research was determined more
generally, and the actors involved, suggests that the
considerable power of the global health agenda, often
aimed at current crises, and the research financing
tied to them, may inhibit the development of a more
varied or context specific local agenda. This is likelye b vaccine
HO and UNICEF. Their arguments were pre-
ningitis disease among children and the ab-
was supported by research data from West
is side. Of course the Ministry of Health was
were no local data to challenge what they
y (Policy-maker 9, F, 14 042005).
mbing to donor pressure, saw an opportunity
structure development and other related ben-
oduction of the vaccine here.we need more
ts would be if we discontinued the vaccine.
n where we are in terms of whether the pneu-
accine but it’s not there.(Policy implementer
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formation, lack of local funds to support research and
weak communication between those delivering health
care (and the communities they serve), policy-makers
and researchers (COHRED, 2002; Tangwa, 2004).
Developing a more locally aligned agenda is, however,
challenging. Local researchers and policy makers, for
instance, can only meaningfully prioritise if they them-
selves are correctly informed. At present, the upward
flow of information, from communities, health pro-
viders and policy implementers, remains weak. While
rectifying this situation will require considerable in-
vestment it seems to be a pre-requisite to the develop-
ment of a broadly based collaborative partnership.
However, there may also be an advantage if na-
tional research institutes retain some autonomy in the
choice of research topic, as some independence and
ability to challenge accepted dogma may provide for
a longer term, more forward-thinking institutional
perspective. The challenge here is the requirement
for long-term funding support that is also critical for
national research institutions to attract and retain local
researchers, and use them in linking research to policy
and practice.
Some of the current efforts to address this perennial
lack of local resources include proposals for specific
research budgets although the government has yet to
commit to such a venture. Other efforts include high
level delegations to funders (including the European
Union, DFID, USAID, The Wellcome Trust and the
Gates Foundation) by policy-makers, to push for the
development of a funding envelope, as opposed to
the current project-specific mode of funding within
the health sector. The proposed mode of funding is ex-
pected to give local stakeholders some autonomy in the
choice of research priorities and in the coordination of
responses to those priorities. The success of these
efforts will require stronger links within the national
health research system, especially among the Ministry
of Health, researchers, universities and those in charge
of implementing health policies. In addition, agencies
that fund health reforms must strive to enlarge the
decision space to accommodate local stakeholders in
determining local health agendas.
Whereas conducting research on identified priori-
ties does not necessarily guarantee its influence on pol-
icy and practice (Global Forum for Health Research,
2004; Hanney, Gonzalez-Block, Buxton, & Kogan,
2003), it is instructive to note that participants in this
study did not specifically mention any attempt to bring
together key stakeholders in health to collaboratively
decide the agenda for health research so as to informpolicy. This is despite the fact that it is widely
acknowledged that such participation is key to facili-
tating ownership and use of research findings in influ-
encing policy and practice (Emanuel et al., 2004;
Gibbons, 1994; Pang, Pablo-Mendez, & IJsselmuiden,
2004). The importance of sustained and effective
partnerships is underscored by our tracer examples.
Although convincing evidence on the emergence of re-
sistance to SP drugs was generated by researchers and
effectively targeted to policy-makers through a MoH
technical working group, policy-makers were reluctant
to take any action until international financing was
agreed. Once the policy and funding were in place,
however, the implementers were hesitant as they
were unaware of the evidence or reason for the policy
change. Meanwhile, the introduction of the Hib vac-
cine importantly shows the danger of global decisions
in the absence of structures to guide and coordinate in-
formation-based collaboration. Although these find-
ings are not entirely surprising, they nevertheless
point to lack of engagement between research, policy
opinion leaders and policy implementers, and the ab-
sence of means through which such engagement can
be framed within a national strategy. Most importantly,
our findings indicate that policy implementers (district
level actors) play an important role in the translation of
research into practice, and therefore efforts to link
research, policy and practice should engage with
them, alongside the policy opinion leaders.
In addition to setting the agenda for research collab-
oratively, dissemination of findings is critical for such
results to influence policy making and practice
(Emanuel et al., 2004). Research findings, however,
influence policy and practice in different ways (Davis
et al., 2003; Lavis, Robertson, Woodside, McLeod, &
Abelson, 2003; Nutley, 2000), and information linkages
between producers and potential users of research must
address the specific needs of each audience. The consid-
erable reliance on traditional means of dissemination,
such as publication in international journals that are
not accessible to local stakeholders (policy-makers
and implementers) may compromise the potential social
value of research. Dissemination strategies should be
guided by a careful analysis of stakeholders who are
likely to act on the basis of the available findings (Ema-
nuel et al., 2004; Estabrooks, 2001; Lavis et al., 2002).
Interestingly, dissemination of research findings within
the two tracers was mainly targeted at the policy-
makers, with an almost total disregard of other relevant
stakeholders who may have been necessary for support-
ing policy formulation and implementation. At the same
time, policy-makers did not consider disseminating
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and the communities at the grassroots level. These
data suggest that frequent miscalculations in the range
of targets for whom research has value may have been
made, although it is also clear that the mechanisms
which may have allowed broad dissemination are
weak or non-existent. It would seem therefore that
attempts to enhance the value of research should be tar-
geted at multiple levels: dissemination to peers, policy
makers, policy implementers and other potential users.
This does not imply a complete mixing of levels and
responsibilities but points to the need for a more interac-
tive model of information sharing between all levels as
opposed to the frequently cited linear paradigm of
research to policy to practice.
The data from the two tracers also point to an ethical
deficiency in the consideration of social value. It can be
argued that a wider recruitment of stakeholders and
broader dissemination of evidence during the anti-
malarial drug policy change and the introduction of
the Hib vaccine may have resulted in more informed de-
cisions and practices and, maybe, enhanced the public
good of international research. These experiences, how-
ever, raise an important ethical dilemma on just how far
the responsibilities of each of the stakeholders involved
in research translation extend. The dilemma has critical
ramifications for the research enterprise, including
problem identification, funding, actual production of
knowledge and the nature of engagement between and
among stakeholders.
Conclusion
Debate on ethics of research in developing countries
has previously addressed the question of what happens
once research is over, with special attention paid to ac-
cess to fair benefits (NBAC, 2004; Shapiro & Benatar,
2004; UNESCO, 2005). In response, international re-
search guidelines and principles have emphasised the
need for prior agreements or collaboration and partner-
ship among stakeholders working in health research to
ensure that the prioritised questions have social value
to the community by way of responding to their health
needs (CIOMS, 2002; NCOB, 2005; UNESCO, 2005).
Data from this exploratory country-based study illus-
trate the need for greater investment to support the
mechanisms and structures to coordinate the collabora-
tive process. Importantly, our study points to a sense of
isolation from the processes of agenda setting among
local researchers and policy implementers and a disre-
gard of policy implementers as a target for knowledge
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